A Phase 3 interventional study of Emapalumab in Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis and Still Disease, sponsored by Swedish Orphan Biovitrum. Completed at 44 sites in 13 countries. Open to participants aged 6 Months to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as per their background disease. The cohorts are defined as follows:
The study has the objectives to investigate the efficacy, safety and tolerability, for 8 weeks, and PK and PD, QoL and immunogenicity in these 2 cohorts for up to 1 year after last dose of of emapalumab.
Macrophage Activation Syndrome (MAS) Secondary Hemophagocytic Lymphohistiocytosis (sHLH) systemic Juvenile Idiopathic Arthritis (sJIA) Adult-onset Still's Disease (AOSD) Systemic Lupus Erythematosus (SLE)
20 studies on the registry are indexed under Macrophage Activation Syndrome; 4 are open to participants now.
This study's enrollment of 33 is close to the median of 33 across 11 interventional studies indexed under Macrophage Activation Syndrome.
Browse Macrophage Activation Syndrome studies →Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Interventional phase in all cohorts
Diagnosis of active MAS confirmed by the treating rheumatologist, having ascertained the followings:
a. Febrile subjects presenting with ferritin > 684 ng/mL. b. and any 2 of: i. count ≤ 181 x109/L ii. -level > 48 U/L iii. Triglycerides > 156 mg/dL iv. Fibrinogen level ≤ 360 mg/dL
Female subjects of willing to use highly effective methods of from study drug initiation to 6 months after the last dose of study drug.
Specific inclusion criteria to Cohort 1 and Cohort 2
Cohort 1:
Cohort 2:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
Drug: Emapalumab
Emapalumab iv infusion
Also known as: NI-0501, emapalumab-lzsg, ATC code: L04AA39 (WHO)
Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab
Resolution of clinical signs and symptoms present at baseline: The macrophage activation syndrome (MAS) clinical activity will be measured on a visual analog scale (VAS) 10 cm. Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10. And Normalization of laboratory parameters relevant to MAS, as follows: WBC above LLN, platelet count above LLN, LDH below 1.5 ULN, ALT below 1.5 ULN, AST below 1.5 ULN, fibrinogen higher than 100 mg/dL, ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is lower
Time frame: 8 weeks
Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First
GC tapering as per investigator discretion
Time frame: At any time within the first 8 weeks from start of emapalumab treatment
Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS).
GC tapering as per investigator discretion
Time frame: At any time in the study, up to 1 year
Time to Achieve GCs Tapering
Median time to achieve GCs tapering to a dose \< 50 % of PDN equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS (in patients already treated for the underlying condition), or to ≤1mg/kg/Day of PDN Equivalent, whichever occurs first at any time during the study GC tapering as per investigator discretion
Time frame: At any time in the study, up to 1 year
Time to First Complete Response (CR)
Time to CR until EOS Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. Definition of CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower.
Time frame: At any time in the study, up to 1 year
Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR)
Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.
Time frame: At week 8
Time to First Overall Response as Defined by CR or PR
Time to first overall response CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.
Time frame: At any time in the study, up to 1 year
MAS Recurrence at Anytime After Achievement of CR
Number of patients with MAS recurrence at anytime after achievement of CR
Time frame: At any time after CR, up to 1 year
Withdrawal From the Study Due to Lack of Response
Number of patients withdrawn from the study due to lack of response as per Investigator decision
Time frame: At any time in the study, up to 1 year
Survival
Number of patients alive at the end of study
Time frame: At end of study, 1 year
Adverse Events (AEs) (Serious and Non-serious).
number of patients that experienced at least one AE (serious and non-serious).
Time frame: At any time in the study, up to 1 year
Study Interruption Due to Safety Reasons
Number of participants withdrawn from study treatment due to adverse event
Time frame: At any time in the study, up to 1 year
Laboratory Parameters
Number of patients with clinically meaningful changes in hematology and chemistry laboratory parameters from baseline
Time frame: At any time in the study, up to 1 year
Patient Reported Outcomes : PedsQL™;
Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions) The PedsQL is scored on a 5-point Likert scale from: 0 (Never) to 4 (Almost always) Then, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0 To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales (this also accounts for missing data). If more than 50% of the items in the scale are missing, the Scale Scores should not be computed. If 50% or more items are completed: Impute the mean of the completed items in a scale
Time frame: Baseline, week 8, 6 months, and EOS (1 year)
Patient Reported Outcomes: Clinician Global Impression of Severity
Health-related quality of life: Global Assessment: Clinician Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the clinician as None, Mild, Moderate, or Severe, at the specified timepoints.
Time frame: Baseline, Week 8, month 6 and EOS (1 year)
Patient Reported Outcomes: Patient/Parent Global Impression of Severity
Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the Patient/Parent as None, Mild, Moderate, or Severe, at the specified timepoints.
Time frame: Screening, Week 8, month 6 and EOS (1 year)
PK Endpoints
Serum concentrations of emapalumab vs. time
Time frame: Baseline (Day 1), week 8, Day 60, Day 100, 6 Months, EOS (1 year)
PD Endpoints Per Cohort: Chemokines
Levels of the main IFN-γ-induced chemokine (CXCL9).
Time frame: Baseline, week 8, 6 months, EOS (1 year)
PD Endpoints Per Cohort: sCD25)
Levels of MAS markers; sCD25 (Soluble CD25 (i.e., soluble IL-2 receptor))
Time frame: Baseline, week 8, 6 months, EOS (1 year)
Immunogenicity Endpoints
Occurrence of ADAs to emapalumab until EOS (1 year after last dose of emapalumab) Baseline and overall incidence
Time frame: At any time in the study, up to 1 year
| Milestone | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Started | 25 | 8 |
| Completed | 23 | 7 |
| Not completed | 2 | 1 |
Resolution of clinical signs and symptoms present at baseline: The macrophage activation syndrome (MAS) clinical activity will be measured on a visual analog scale (VAS) 10 cm. Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity will be measured on a visual analog scale (VAS) 10 cm. Clinical signs will be considered as resolved if VAS is below or equal to 1/10. And Normalization of laboratory parameters relevant to MAS, as follows: WBC above LLN, platelet count above LLN, LDH below 1.5 ULN, ALT below 1.5 ULN, AST below 1.5 ULN, fibrinogen higher than 100 mg/dL, ferritin levels decreased by at least 80 % from values at screening or baseline (whichever is higher) or below 2000 ng/ml, whichever is lower
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab | 11 | 4 |
GC tapering as per investigator discretion
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First | 15 | 7 |
GC tapering as per investigator discretion
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Number of Patients With GCs Tapering to ≤1mg/kg/Day of PDN Equivalent at Any Time Until End of Study (EOS). | 19 | 6 |
Median time to achieve GCs tapering to a dose \< 50 % of PDN equivalent at the time of emapalumab start or to the same (or lower) dose being administered before the occurrence of MAS (in patients already treated for the underlying condition), or to ≤1mg/kg/Day of PDN Equivalent, whichever occurs first at any time during the study GC tapering as per investigator discretion
| weeks | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Time to Achieve GCs Tapering | 5 (2.0 to 10.0) | 1 (1.0 to 5.0) |
Time to CR until EOS Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. Definition of CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower.
| weeks | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Time to First Complete Response (CR) | 8.4 (5.0 to 20.9) | 5.9 (3.4 to NA) |
Resolution of clinical signs and symptoms present at baseline: The MAS clinical activity was measured on a visual analog scale (VAS) 10 cm. CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR) | 16 | 6 |
Time to first overall response CR: Resolution of clinical signs and symptoms present at baseline: MAS clinical activity was measured on a 10-cm VAS. Clinical signs were considered resolved if VAS was below or equal to 1/10. and Normalization of laboratory parameters relevant to MAS as follows: * WBC \>LLN. * Platelet count \>LLN. * LDH \<1.5 ULN. * ALT \<1.5 ULN. * AST \<1.5 ULN. * Fibrinogen \>100 mg/dL. * Ferritin levels decreased by at least 80% from values at Screening or baseline (whichever was higher) or \<2000 ng/mL, whichever was lower. PR: Resolution or improvement in clinical signs and symptoms measured by the MAS clinical activity on the VAS. The patient was classified as PR if he or she presented a VAS \<4/10. and Normalization of at least 3 of the abnormal baseline laboratory parameters relevant to MAS, as defined above.
| weeks | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Time to First Overall Response as Defined by CR or PR | 2.9 (1.4 to 8.4) | 3.7 (0.6 to NA) |
Number of patients with MAS recurrence at anytime after achievement of CR
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| MAS Recurrence at Anytime After Achievement of CR | 4 | 1 |
Number of patients withdrawn from the study due to lack of response as per Investigator decision
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Withdrawal From the Study Due to Lack of Response | 0 | 0 |
Number of patients alive at the end of study
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Survival | 23 | 8 |
number of patients that experienced at least one AE (serious and non-serious).
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Adverse Events (AEs) (Serious and Non-serious). | 24 | 8 |
Number of participants withdrawn from study treatment due to adverse event
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Study Interruption Due to Safety Reasons | 1 | 1 |
Number of patients with clinically meaningful changes in hematology and chemistry laboratory parameters from baseline
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Laboratory Parameters | 0 | 0 |
Pediatric Quality of Life Inventory (PedsQL™; Generic Core Scales and Infant Scales, Acute versions) The PedsQL is scored on a 5-point Likert scale from: 0 (Never) to 4 (Almost always) Then, for ease of interpretability, items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better HRQOL (Health-Related Quality of Life). To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0 To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales (this also accounts for missing data). If more than 50% of the items in the scale are missing, the Scale Scores should not be computed. If 50% or more items are completed: Impute the mean of the completed items in a scale
| score on a scale | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline | 43.18 ± 21.488 | 51.45 ± 25.955 |
| Week 8 | 67.88 ± 21.617 | 79.35 ± NA |
| 6 months | 72.85 ± 16.650 | 85.87 ± 16.909 |
| EOS (1 year) | 80.79 ± 18.020 | 97.83 ± NA |
Health-related quality of life: Global Assessment: Clinician Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the clinician as None, Mild, Moderate, or Severe, at the specified timepoints.
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline — none | 0 | 0 |
| Baseline — mild | 1 | 1 |
| Baseline — moderate | 15 | 1 |
| Baseline — severe | 9 | 6 |
| Week 8 — none | 11 | 6 |
| Week 8 — mild | 5 | 1 |
| Week 8 — moderate | 3 | 0 |
| Week 8 — severe | 0 | 0 |
| Month 6 — none | 16 | 5 |
| Month 6 — mild | 1 | 1 |
| Month 6 — moderate | 0 | 0 |
| Month 6 — severe | 0 | 0 |
| EOS (1 year) — none | 17 | 4 |
| EOS (1 year) — mild | 3 | 0 |
| EOS (1 year) — moderate | 0 | 1 |
| EOS (1 year) — severe | 0 | 0 |
Health-related quality of life: Global Assessment: Patient/Parent Global Impression of Severity Number of patients having an overall severity of the health status over the past week assessed by the Patient/Parent as None, Mild, Moderate, or Severe, at the specified timepoints.
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline — none | 0 | 0 |
| Baseline — mild | 1 | 1 |
| Baseline — moderate | 15 | 1 |
| Baseline — severe | 9 | 6 |
| Week 8 — none | 11 | 6 |
| Week 8 — mild | 5 | 1 |
| Week 8 — moderate | 3 | 0 |
| Week 8 — severe | 0 | 0 |
| Month 6 — none | 16 | 5 |
| Month 6 — mild | 1 | 1 |
| Month 6 — moderate | 0 | 0 |
| Month 6 — severe | 0 | 0 |
| EOS (1 year) — none | 17 | 4 |
| EOS (1 year) — mild | 3 | 0 |
| EOS (1 year) — moderate | 0 | 1 |
| EOS (1 year) — severe | 0 | 0 |
Serum concentrations of emapalumab vs. time
| ng/mL | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline (Day 1) | 112541.47 ± 43924.399 | 167990.22 ± 77376.997 |
| Week 8 | 170691.64 ± 220467.041 | 81457.69 ± 126004.837 |
| Day 60 | 44314.88 ± 59798.354 | 19532.33 ± 23182.423 |
| Day 100 | 15807.32 ± 26206.224 | 8596.18 ± 10611.686 |
| 6 Months | 2215.22 ± 4545.3 | 1460.33 ± 1281.8 |
| EOS (1 year) | 889.11 ± 3921.266 | 74817.54 ± 167195.974 |
Levels of the main IFN-γ-induced chemokine (CXCL9).
| ng/L | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline | 21344.26 ± 79546.837 | 2352.57 ± 3674.773 |
| Week 8 | 96.43 ± 128.617 | 134.70 ± 149.996 |
| 6 months | 1095.19 ± 2677.991 | 183.74 ± 126.758 |
| EOS (1 year) | 293.05 ± 441.078 | 123.12 ± 62.820 |
Levels of MAS markers; sCD25 (Soluble CD25 (i.e., soluble IL-2 receptor))
| ng/L | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline | 21287.45 ± 34921.520 | 4893.50 ± 2113.562 |
| Week 8 | 3915.58 ± 2251.457 | 2336.40 ± 810.798 |
| Month 6 | 3967.38 ± 4018.122 | 3424.00 ± 1371.916 |
| EOS (1 year) | 3456.40 ± 3630.806 | 3515.40 ± 2809.668 |
Occurrence of ADAs to emapalumab until EOS (1 year after last dose of emapalumab) Baseline and overall incidence
| Participants | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Baseline ADA | 0 | 0 |
| overall ADA incidence | 5 | 0 |
Collected over From signature of informed consent (i.e. screening) until EOS (1 year). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 (sJIA and AOSD) | 2/25 (8%) | 18/25 (72%) | 24/25 (96%) |
| Cohort 2 (SLE) | 0/8 (0%) | 4/8 (50%) | 8/8 (100%) |
| Event | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Still's diseaseMusculoskeletal and connective tissue disorders | 6/25 | 0/8 |
| PneumoniaInfections and infestations | 5/25 | 0/8 |
| Condition aggravatedGeneral disorders | 4/25 | 1/8 |
| Lupus nephritisRenal and urinary disorders | 0/25 | 1/8 |
| Abscess limbInfections and infestations | 0/25 | 1/8 |
| Prothrombin level decreasedInvestigations | 0/25 | 1/8 |
| Cytomegalovirus infectionInfections and infestations | 2/25 | 0/8 |
| Herpes ZosterInfections and infestations | 2/25 | 0/8 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 2/25 | 0/8 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/25 | 0/8 |
| Event | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/25 | 3/8 |
| Still's diseaseMusculoskeletal and connective tissue disorders | 8/25 | 0/8 |
| AnaemiaBlood and lymphatic system disorders | 7/25 | 0/8 |
| Cytomegalovirus infectionInfections and infestations | 3/25 | 2/8 |
| SinusitisInfections and infestations | 2/25 | 2/8 |
| Epstein-Barr virus infectionInfections and infestations | 0/25 | 2/8 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/25 | 2/8 |
| RashSkin and subcutaneous tissue disorders | 3/25 | 2/8 |
| ConstipationGastrointestinal disorders | 0/25 | 2/8 |
| Lupus nephritisRenal and urinary disorders | 0/25 | 2/8 |
| Age, Categorical(Participants) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| <=18 years | 17 | 4 | 21 |
| Between 18 and 65 years | 8 | 4 | 12 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| Mean | 15.8 ± 15.54 | 14.6 ± 6.78 | 15.5 ± 13.83 |
| Sex: Female, Male(Participants) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| Female | 21 | 5 | 26 |
| Male | 4 | 3 | 7 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 22 | 7 | 29 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 18 | 2 | 20 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 0 | 3 |
| Region of Enrollment(participants) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| United States | 2 | 4 | 6 |
| Czechia | 4 | 0 | 4 |
| Japan | 2 | 0 | 2 |
| United Kingdom | 2 | 0 | 2 |
| Spain | 2 | 1 | 3 |
| Canada | 1 | 1 | 2 |
| Netherlands | 2 | 0 | 2 |
| Belgium | 1 | 0 | 1 |
| China | 1 | 2 | 3 |
| Italy | 4 | 0 | 4 |
| France | 2 | 0 | 2 |
| Germany | 2 | 0 | 2 |
| Body weight(kg) | Cohort 1 (sJIA and AOSD) | Cohort 2 (SLE) | Total |
|---|---|---|---|
| Mean | 44.48 ± 21.777 | 49.46 ± 33.990 | 45.69 ± 24.761 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Jun 2024, 30 months.
Results were first posted in Feb 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emapalumab
Macrophage Activation Syndrome →